J0577
HCPCSInj, brixadi, 7 days or less
Official HCPCS Level II long descriptor
Injection, buprenorphine extended-release (brixadi), less than or equal to 7 days of therapy
HCPCS Level II code J0577 is maintained by CMS and is active in the current quarterly release.
Short descriptor
Inj, brixadi, 7 days or less
Added to HCPCS: 2024-04-01
Nearby codes in J0
- J0565Inj, bezlotoxumab, 10 mg
- J0567Inj., cerliponase alfa 1 mg
- J0570Buprenorphine implant 74.2mg
- J0571Buprenorphine oral 1mg
- J0572Bupren/nal up to 3mg bupreno
- J0573Bupren/nal 3.1 to 6mg bupren
- J0574Bupren/nal 6.1 to 10mg bupre
- J0575Bupren/nal over 10mg bupreno
- J0578Inj brixadi, more than 7 day
- J0582Bivalirudin (endo) 1 mg
- J0583Bivalirudin
- J0584Injection, burosumab-twza 1m
- J0585Injection,onabotulinumtoxina
- J0586Abobotulinumtoxina
- J0587Inj, rimabotulinumtoxinb
- J0588Incobotulinumtoxin a
Where this code sits
Krasyn AI Coder
Get code suggestions automatically as you type notes. Free for 50 analyses.
Install for Chrome — freeSource
HCPCS Level II July 2026 quarterly update. Centers for Medicare & Medicaid Services (CMS), “July 2026 Alpha-Numeric HCPCS File” (HCPC2026_JUL_ANWEB_06172026.txt). Download the original file from cms.gov. Public domain (US Government work). Descriptors, billable flags and instructional notes on this page are reproduced from that file without modification. Krasyn adds no clinical guidance.